

STIC-Biotech/ChemLib

162242

From: Bowman, Amy
Sent: Thursday, August 11, 2005 11:46 AM
To: STIC-Biotech/ChemLib
Cc: Bowman, Amy
Subject: sequence search-10/665,951

Hello,
I need SEQ ID NO: 2185 searched in application 10/665,951, length limited to 30 nucleotides.
Thank you,
Amy Bowman
AU 1635
REM 2C31
mail REM 2C18
571-272-0755

EDWARD HART

10/11/05
11:46 AM
STIC-Biotech/ChemLib

STAFF USE ONLY

Searcher: _____
Searcher Phone: 2- _____
Date Searcher Picked up: 8/17/05
Date Completed: 8/19/05
Searcher Prep/Rev. Time: _____
Online Time: _____

Type of Search

NA#: 1 AA#: _____
Interference: _____ SPDI: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure#: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable

STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: ESP
WWW/Internet: _____
Other(Specify): _____

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:19:12 ; Search time 1735 Seconds
(without alignments)
159.172 Million cell updates/sec

Title: US-10-665-951-2185

Perfect score: 21

Sequence: 1 cugaguuaaagcaccm 21

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Searched: 23768202 seqs, 6575307184 residues

Total number of hits satisfying chosen parameters: 32118462

Minimum DB seq length: 0

Maximum DB seq length: 30

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending Patents NA New:

```
1: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq.*
2: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq2.*
3: /cgn2_6/ptodata/1/pna/US06_NEW_COMB.seq.*
4: /cgn2_6/ptodata/1/pna/US07_NEW_COMB.seq.*
5: /cgn2_6/ptodata/1/pna/US08_NEW_COMB.seq.*
6: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq.*
7: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq1.*
8: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq2.*
9: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq.*
10: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq10.*
11: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq2.*
12: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq3.*
13: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq4.*
14: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq5.*
15: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq6.*
16: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq7.*
17: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq8.*
18: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq9.*
19: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq.*
20: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq2.*
21: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq3.*
22: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq4.*
23: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq5.*
24: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq6.*
25: /cgn2_6/ptodata/1/pna/US60_NEW_COMB.seq.*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Score	Match	Length	ID	Description
C 1	19	90.5	19	13	US-10-944-611-2809
C 2	19	90.5	19	13	US-10-944-611-2967
C 3	19	90.5	19	13	US-10-944-611-2977
C 4	19	90.5	19	13	US-10-944-611-3139
C 5	19	90.5	19	13	US-10-944-611-3141
C 6	19	90.5	19	13	US-10-944-611-3143
C 7	19	90.5	19	13	US-10-944-611-3144
C 8	19	90.5	19	14	US-10-962-898-2809
C 1	19	90.5	19	13	Sequence 2809, Ap
C 2	19	90.5	19	13	Sequence 2967, Ap
C 3	19	90.5	19	13	Sequence 2977, Ap
C 4	19	90.5	19	13	Sequence 3139, Ap
C 5	19	90.5	19	13	Sequence 3141, Ap
C 6	19	90.5	19	13	Sequence 3143, Ap
C 7	19	90.5	19	13	Sequence 3144, Ap
C 8	19	90.5	19	14	Sequence 2809, Ap

9	19	90.5	19	14	US-10-962-898-2967	Sequence 2967, Ap
10	19	90.5	19	14	US-10-962-898-2977	Sequence 2977, Ap
11	19	90.5	19	14	US-10-962-898-3139	Sequence 3139, Ap
12	19	90.5	19	14	US-10-962-898-3141	Sequence 3141, Ap
13	19	90.5	19	14	US-10-962-898-3143	Sequence 3143, Ap
14	19	90.5	19	14	US-10-962-898-3144	Sequence 3144, Ap
15	19	90.5	20	13	US-10-944-611-2966	Sequence 2966, Ap
16	19	90.5	20	13	US-10-944-611-2976	Sequence 2976, Ap
17	19	90.5	20	14	US-10-962-898-2966	Sequence 2966, Ap
18	19	90.5	20	14	US-10-962-898-2976	Sequence 2976, Ap
19	19	90.5	21	9	US-10-727-780A-23	Sequence 23, Appl
20	19	90.5	21	9	US-10-727-780A-24	Sequence 24, Appl
21	19	90.5	21	13	US-10-944-611-2742	Sequence 2742, Ap
22	19	90.5	21	13	US-10-944-611-2745	Sequence 2745, Ap
23	19	90.5	21	13	US-10-944-611-2763	Sequence 2763, Ap
24	19	90.5	21	13	US-10-944-611-2765	Sequence 2765, Ap
25	19	90.5	21	13	US-10-944-611-2767	Sequence 2767, Ap
26	19	90.5	21	13	US-10-944-611-2769	Sequence 2769, Ap
27	19	90.5	21	13	US-10-944-611-2777	Sequence 2777, Ap
28	19	90.5	21	13	US-10-944-611-2778	Sequence 2778, Ap
29	19	90.5	21	13	US-10-944-611-2843	Sequence 2843, Ap
30	19	90.5	21	13	US-10-944-611-2844	Sequence 2844, Ap
31	19	90.5	21	13	US-10-944-611-2845	Sequence 2845, Ap
32	19	90.5	21	13	US-10-944-611-2846	Sequence 2846, Ap
33	19	90.5	21	13	US-10-944-611-2864	Sequence 2864, Ap
34	19	90.5	21	13	US-10-944-611-2865	Sequence 2865, Ap
35	19	90.5	21	13	US-10-944-611-2868	Sequence 2868, Ap
36	19	90.5	21	13	US-10-944-611-2872	Sequence 2872, Ap
37	19	90.5	21	13	US-10-944-611-2876	Sequence 2876, Ap
38	19	90.5	21	13	US-10-944-611-2880	Sequence 2880, Ap
39	19	90.5	21	13	US-10-944-611-2925	Sequence 2925, Ap
40	19	90.5	21	13	US-10-944-611-2928	Sequence 2928, Ap
41	19	90.5	21	13	US-10-944-611-2931	Sequence 2931, Ap
42	19	90.5	21	13	US-10-944-611-2934	Sequence 2934, Ap
43	19	90.5	21	13	US-10-944-611-2937	Sequence 2937, Ap
44	19	90.5	21	13	US-10-944-611-2940	Sequence 2940, Ap
45	19	90.5	21	13	US-10-944-611-2953	Sequence 2953, Ap

ALIGNMENTS

RESULT 1

```
US-10-944-611-2809/c
; Sequence 2809, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
```

```
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2809
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: X stands for nitroindole universal base
; US-10-944-611-2809

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAAGGCACCC 1
|:|||||:|||||:|||||

RESULT 2
US-10-944-611-2967
; Sequence 2967, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2967
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; US-10-944-611-2977

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 1 CUGAGUUUAAAAGGCACCC 19
|:|||||:|||||:|||||

RESULT 3
US-10-944-611-2977/c
; Sequence 2977, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2977
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; US-10-944-611-2977

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:|||||:|||||:|||||
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; US-10-944-611-2967

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 1 CUGAGUUUAAAAGGCACCC 19
|:|||||:|||||:|||||

RESULT 3
US-10-944-611-2977/c
; Sequence 2977, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2977
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; US-10-944-611-2977

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:|||||:|||||:|||||
```

```
Db      19 CTGAGTTTTAAAGGCACCC 1
RESULT 4
US-10-944-611-3139
; Sequence 3139, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
US-10-944-611-3139
Query Match      90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy      1 CUGAGUUUAAAAGGCACCC 19
Db      1 CUGAGUUUAAAAGGCACCC 19
RESULT 5
US-10-944-611-3141/c
; Sequence 3141, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/235 (MBHB02-742-S)
```

```
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3141
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
US-10-944-611-3141
Query Match      90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Oy      1 CUGAGUUUAAAAGGCACCC 19
Db      19 CTGAGTTTTAAAGGCACCC 1
RESULT 6
US-10-944-611-3143
; Sequence 3143, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
```

```

; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3143
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; US-10-944-611-3143

```

```

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 CUGAGUUUAAAGGCACCC 19
|:|||||
Db 1 CUGAGUUUAAAGGCACCC 19

```

```

RESULT 7
US-10-944-611-3144/c
; Sequence 3144, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
;

```

```

; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3144
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(14)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-O-methyl
; US-10-944-611-3144

```

```

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 CUGAGUUUAAAGGCACCC 19
|:|||||
Db 19 CTGAGTTTAAAGGCACCC 1

```

```

RESULT 8
US-10-962-898-2809/c
; Sequence 2809, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
;

```

; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2809
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: X stands for nitroindole universal base
US-10-962-898-2809

Query Match 90.5%; Score 19; DB 14; Length 19;

Best Local Similarity 78.9%; Pred. No. 8.4; Indels 0; Gaps 0;

Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 9

US-10-962-898-2967
; Sequence 2967, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBH02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2977
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-962-898-2977

Query Match 90.5%; Score 19; DB 14; Length 19;

Best Local Similarity 100.0%; Pred. No. 8.4; Indels 0; Gaps 0;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2967
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
US-10-962-898-2967

Query Match 90.5%; Score 19; DB 14; Length 19;

Best Local Similarity 100.0%; Pred. No. 8.4; Indels 0; Gaps 0;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 10

US-10-962-898-2977/c
; Sequence 2977, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBH02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2977
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-962-898-2977

Query Match

90.5%; Score 19; DB 14; Length 19;

```
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 11
US-10-962-898-3139
; Sequence 3139, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
US-10-962-898-3141

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 13
US-10-962-898-3143
; Sequence 3143, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; CURRENT APPLICATION NUMBER: PCT/US03/05022
;

US-10-962-898-3141/c
; Sequence 3141, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
```

```
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3141
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
US-10-962-898-3141

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 13
US-10-962-898-3143
; Sequence 3143, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; CURRENT APPLICATION NUMBER: PCT/US03/05022
;

US-10-962-898-3141/c
; Sequence 3141, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
```


; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3143
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
US-10-962-898-3143

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|||||:|||||
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 14
US-10-962-898-3144/c
; Sequence 3144, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348

; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3144
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(14)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-O-methyl
US-10-962-898-3144

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:|||||:|||||
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 15
US-10-944-611-2966
; Sequence 2966, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23

```

; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2966
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
US-10-944-611-2966

Query Match          90.5%; Score 19; DB 13; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0

Qy 1 CUGAGUUUAAAAGGCACCC 19
   |||||||
Db 1 CUGAGUUUAAAAGGCACCC 19

Search completed: August 19, 2005, 00:02:13
Job time : 1736 secs

```

Pending Nucleic Acid and Pending Amino Acid database searches generate two sets of results each. The Pending databases have been split into two parts to reduce the amount of time required for their daily updates. This results in more machine time being available for processing searches.

Searches run against the Nucleic Acid Pending database produce two sets of results, with the extensions .rnpm and .rnpn

Searches run against the Amino Acid Pending database produce two sets of results, with the extensions .rapm and .rapn

Because they contain data that is confidential, the results of Pending database searches should not be left in the case .

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:15:08 ; Search time 3829 Seconds
(without alignments)
223.892 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaggaccmnn 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 45554873 seqs, 20411521753 residues
Total number of hits satisfying chosen parameters: 35943252

Minimum DB seq length: 0
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending Patents NA Main.*

1: /cgn2_6/ptodata/1/pna/PCRTUS1_COMB.seq.*
2: /cgn2_6/ptodata/1/pna/PCRTUS2_COMB.seq.*
3: /cgn2_6/ptodata/1/pna/PCRTUS_COMB.seq.*
4: /cgn2_6/ptodata/1/pna/US06_COMB.seq.*
5: /cgn2_6/ptodata/1/pna/US07_COMB.seq.*
6: /cgn2_6/ptodata/1/pna/US080_COMB.seq.*
7: /cgn2_6/ptodata/1/pna/US081_COMB.seq.*
8: /cgn2_6/ptodata/1/pna/US082_COMB.seq.*
9: /cgn2_6/ptodata/1/pna/US083_COMB.seq.*
10: /cgn2_6/ptodata/1/pna/US084_COMB.seq.*
11: /cgn2_6/ptodata/1/pna/US085_COMB.seq.*
12: /cgn2_6/ptodata/1/pna/US086_COMB.seq.*
13: /cgn2_6/ptodata/1/pna/US087_COMB.seq.*
14: /cgn2_6/ptodata/1/pna/US088_COMB.seq.*
15: /cgn2_6/ptodata/1/pna/US089_COMB.seq.*
16: /cgn2_6/ptodata/1/pna/US090_COMB.seq.*
17: /cgn2_6/ptodata/1/pna/US091_COMB.seq.*
18: /cgn2_6/ptodata/1/pna/US092A_COMB.seq.*
19: /cgn2_6/ptodata/1/pna/US092B_COMB.seq.*
20: /cgn2_6/ptodata/1/pna/US093A_COMB.seq.*
21: /cgn2_6/ptodata/1/pna/US093B_COMB.seq.*
22: /cgn2_6/ptodata/1/pna/US094_COMB.seq.*
23: /cgn2_6/ptodata/1/pna/US095A_COMB.seq.*
24: /cgn2_6/ptodata/1/pna/US095B_COMB.seq.*
25: /cgn2_6/ptodata/1/pna/US095C_COMB.seq.*
26: /cgn2_6/ptodata/1/pna/US095D_COMB.seq.*
27: /cgn2_6/ptodata/1/pna/US096A_COMB.seq.*
28: /cgn2_6/ptodata/1/pna/US096B_COMB.seq.*
29: /cgn2_6/ptodata/1/pna/US096C_COMB.seq.*
30: /cgn2_6/ptodata/1/pna/US096D_COMB.seq.*
31: /cgn2_6/ptodata/1/pna/US096E_COMB.seq.*
32: /cgn2_6/ptodata/1/pna/US097A_COMB.seq.*
33: /cgn2_6/ptodata/1/pna/US097B_COMB.seq.*
34: /cgn2_6/ptodata/1/pna/US097C_COMB.seq.*
35: /cgn2_6/ptodata/1/pna/US098A_COMB.seq.*
36: /cgn2_6/ptodata/1/pna/US098B_COMB.seq.*
37: /cgn2_6/ptodata/1/pna/US098C_COMB.seq.*
38: /cgn2_6/ptodata/1/pna/US098D_COMB.seq.*
39: /cgn2_6/ptodata/1/pna/US099A_COMB.seq.*
40: /cgn2_6/ptodata/1/pna/US099B_COMB.seq.*
41: /cgn2_6/ptodata/1/pna/US099C_COMB.seq.*
42: /cgn2_6/ptodata/1/pna/US099D_COMB.seq.*
43: /cgn2_6/ptodata/1/pna/US099E_COMB.seq.*

44: /cgn2_6/ptodata/1/pna/US099F_COMB.seq.*
45: /cgn2_6/ptodata/1/pna/US099G_COMB.seq.*
46: /cgn2_6/ptodata/1/pna/US100A_COMB.seq.*
47: /cgn2_6/ptodata/1/pna/US100B_COMB.seq.*
48: /cgn2_6/ptodata/1/pna/US101A_COMB.seq.*
49: /cgn2_6/ptodata/1/pna/US101B_COMB.seq.*
50: /cgn2_6/ptodata/1/pna/US102A_COMB.seq.*
51: /cgn2_6/ptodata/1/pna/US102B_COMB.seq.*
52: /cgn2_6/ptodata/1/pna/US103A_COMB.seq.*
53: /cgn2_6/ptodata/1/pna/US103B_COMB.seq.*
54: /cgn2_6/ptodata/1/pna/US104A_COMB.seq.*
55: /cgn2_6/ptodata/1/pna/US104B_COMB.seq.*
56: /cgn2_6/ptodata/1/pna/US105A_COMB.seq.*
57: /cgn2_6/ptodata/1/pna/US105B_COMB.seq.*
58: /cgn2_6/ptodata/1/pna/US106A_COMB.seq.*
59: /cgn2_6/ptodata/1/pna/US107A_COMB.seq.*
60: /cgn2_6/ptodata/1/pna/US107B_COMB.seq.*
61: /cgn2_6/ptodata/1/pna/US107C_COMB.seq.*
62: /cgn2_6/ptodata/1/pna/US107D_COMB.seq.*
63: /cgn2_6/ptodata/1/pna/US108A_COMB.seq.*
64: /cgn2_6/ptodata/1/pna/US108B_COMB.seq.*
65: /cgn2_6/ptodata/1/pna/US109A_COMB.seq.*
66: /cgn2_6/ptodata/1/pna/US109B_COMB.seq.*
67: /cgn2_6/ptodata/1/pna/US109C_COMB.seq.*
68: /cgn2_6/ptodata/1/pna/US110_COMB.seq.*
69: /cgn2_6/ptodata/1/pna/US6000_COMB.seq.*
70: /cgn2_6/ptodata/1/pna/US6001_COMB.seq.*
71: /cgn2_6/ptodata/1/pna/US6002_COMB.seq.*
72: /cgn2_6/ptodata/1/pna/US6003_COMB.seq.*
73: /cgn2_6/ptodata/1/pna/US6004_COMB.seq.*
74: /cgn2_6/ptodata/1/pna/US6005_COMB.seq.*
75: /cgn2_6/ptodata/1/pna/US6006_COMB.seq.*
76: /cgn2_6/ptodata/1/pna/US6007_COMB.seq.*
77: /cgn2_6/ptodata/1/pna/US6008_COMB.seq.*
78: /cgn2_6/ptodata/1/pna/US6009_COMB.seq.*
79: /cgn2_6/ptodata/1/pna/US6010_COMB.seq.*
80: /cgn2_6/ptodata/1/pna/US6011_COMB.seq.*
81: /cgn2_6/ptodata/1/pna/US6012_COMB.seq.*
82: /cgn2_6/ptodata/1/pna/US6013_COMB.seq.*
83: /cgn2_6/ptodata/1/pna/US6014_COMB.seq.*
84: /cgn2_6/ptodata/1/pna/US6015_COMB.seq.*
85: /cgn2_6/ptodata/1/pna/US6016_COMB.seq.*
86: /cgn2_6/ptodata/1/pna/US6017_COMB.seq.*
87: /cgn2_6/ptodata/1/pna/US6018_COMB.seq.*
88: /cgn2_6/ptodata/1/pna/US6019_COMB.seq.*
89: /cgn2_6/ptodata/1/pna/US6020_COMB.seq.*
90: /cgn2_6/ptodata/1/pna/US6021_COMB.seq.*
91: /cgn2_6/ptodata/1/pna/US6022_COMB.seq.*
92: /cgn2_6/ptodata/1/pna/US6023A_COMB.seq.*
93: /cgn2_6/ptodata/1/pna/US6023B_COMB.seq.*
94: /cgn2_6/ptodata/1/pna/US6024_COMB.seq.*
95: /cgn2_6/ptodata/1/pna/US6025_COMB.seq.*
96: /cgn2_6/ptodata/1/pna/US6026_COMB.seq.*
97: /cgn2_6/ptodata/1/pna/US6027_COMB.seq.*
98: /cgn2_6/ptodata/1/pna/US6028_COMB.seq.*
99: /cgn2_6/ptodata/1/pna/US6029_COMB.seq.*
100: /cgn2_6/ptodata/1/pna/US6030_COMB.seq.*
101: /cgn2_6/ptodata/1/pna/US6031_COMB.seq.*
102: /cgn2_6/ptodata/1/pna/US6032_COMB.seq.*
103: /cgn2_6/ptodata/1/pna/US6033_COMB.seq.*
104: /cgn2_6/ptodata/1/pna/US6034_COMB.seq.*
105: /cgn2_6/ptodata/1/pna/US6035_COMB.seq.*
106: /cgn2_6/ptodata/1/pna/US6036_COMB.seq.*
107: /cgn2_6/ptodata/1/pna/US6037_COMB.seq.*
108: /cgn2_6/ptodata/1/pna/US6038_COMB.seq.*
109: /cgn2_6/ptodata/1/pna/US6039_COMB.seq.*
110: /cgn2_6/ptodata/1/pna/US6040_COMB.seq.*
111: /cgn2_6/ptodata/1/pna/US6041_COMB.seq.*
112: /cgn2_6/ptodata/1/pna/US6042_COMB.seq.*
113: /cgn2_6/ptodata/1/pna/US6043_COMB.seq.*
114: /cgn2_6/ptodata/1/pna/US6044_COMB.seq.*
115: /cgn2_6/ptodata/1/pna/US6045_COMB.seq.*
116: /cgn2_6/ptodata/1/pna/US6046_COMB.seq.*


```

? PRIOR APPLICATION NUMBER: US 60/393,796
? PRIOR FILING DATE: 2002-07-03
? PRIOR APPLICATION NUMBER: US 10/287,949
? PRIOR FILING DATE: 2002-11-04
? PRIOR APPLICATION NUMBER: US 10/306,747
? PRIOR FILING DATE: 2002-11-27
? PRIOR APPLICATION NUMBER: PCT/US 02/17674
? PRIOR FILING DATE: 2002-05-29
? PRIOR APPLICATION NUMBER: US 60/358,580
? PRIOR FILING DATE: 2002-02-20
? PRIOR APPLICATION NUMBER: US 60/363,124
? PRIOR FILING DATE: 2002-03-11
? Remaining Prior Application data removed - See File Wrapper or PALM.
? NUMBER OF SEQ ID NOS: 2751
? SOFTWARE: PatentIn version 3.3
? SEQ ID NO 2313
? LENGTH: 19
? TYPE: RNA
? ORGANISM: Artificial Sequence
? FEATURE:
? OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
? FEATURE:
? NAME/KEY: misc feature
? LOCATION: (20)..(20)
? OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
? FEATURE:
? NAME/KEY: misc_feature
? LOCATION: (20)..(20)
? OTHER INFORMATION: X stands for nitroindole universal base
US-10-758-155-2313

Query Match          90.5%; Score 19; DB 62; Length 19;
Best Local Similarity 78.9%; Pred. No. 12;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1  CUGAGUUUAAAAGGCACCC 19
Db      19  CTGAGTTTAAAGGCACCC 1

```

```

US-10-631-620-23157C
; Sequence 2313, Application US/10831620
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MEHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255

```

```

; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: X stands for nitroindole universal base
; US-10-844-076-2313

Query Match          90.5%; Score 19; DB 63; Length 19;
Best Local Similarity 78.9%; Pred.No.12;
Matches 19; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
    |:|:|:|:|:|:|:|:|:|
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 6
PCT-US03-05028-390
; Sequence 390, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fossnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 390
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; PCT-US03-05028-390

Query Match          90.5%; Score 19; DB 2; Length 21;

```



```

Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAAGGCACCC 19
   |||||
Db 1 CUGAGUUUAAAAAGGCACCC 19

RESULT 7
PCT-US03-05028-394/c
; Sequence 394, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Poenaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 394
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
PCT-US03-05028-394

Query Match 90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 79.9%; Pred. No. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAAGGCACCC 19
   |||||
Db 19 CTGAGTTTAAAGGCACCC 19

RESULT 8
PCT-US03-05028-398

```

```
Db      1  CUGAGUUUAAAAGGCACCC 19
|||||
RESULT 9
PCT-US03-05028-402/c
; Sequence 402, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 402
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
PCT-US03-05028-402
Query Match          90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 78.9%; Pred. No. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1  CUGAGUUUAAAAGGCACCC 19
Db      19  CTGAGTTTAAAAGGCACCC 1
|||||
RESULT 10
PCT-US03-05028-447
; Sequence 447, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 447
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
PCT-US03-05028-450/c
Query Match          90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  CUGAGUUUAAAAGGCACCC 19
Db      1  CUGAGUUUAAAAGGCACCC 19
|||||
RESULT 11
PCT-US03-05028-450/c
; Sequence 450, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 447
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
PCT-US03-05028-447
```

; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 450
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
PCT-US03-05028-450

Query Match 90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 78.9%; Pred. No. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Oy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||||
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 12

PCT-US03-05028-453

Sequence 453, Application PC/TUS0305028

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.

APPLICANT: McSwiggen, James

APPLICANT: Beigelman, Leonid

APPLICANT: Chowrira, Bharat

APPLICANT: Pavco, Pamela

APPLICANT: Fossnaugh, Kathy

APPLICANT: Jamison, Sharon

APPLICANT: Usman, Nassim

APPLICANT: Thompson, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using

FILE REFERENCE: 400/104 (MBHB 03-198)

CURRENT APPLICATION NUMBER: PCT/US03/05028

CURRENT FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/363,124

PRIOR FILING DATE: 2002-03-11

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

PRIOR APPLICATION NUMBER: US 60/386,782

PRIOR FILING DATE: 2002-06-06

PRIOR APPLICATION NUMBER: US 60/406,784

PRIOR FILING DATE: 2002-08-29

PRIOR APPLICATION NUMBER: US 60/408,378

PRIOR FILING DATE: 2002-09-05

PRIOR APPLICATION NUMBER: US 60/409,293

PRIOR FILING DATE: 2002-09-09

PRIOR APPLICATION NUMBER: US 60/440,129

PRIOR FILING DATE: 2003-01-15

NUMBER OF SEQ ID NOS: 932

SOFTWARE: PatentIn version 3.2

SEQ ID NO 453

LENGTH: 21

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siNA sense region

FEATURE:

NAME/KEY: misc_feature

LOCATION: (1)..(2)

OTHER INFORMATION: 2'-deoxy-2'-fluoro

FEATURE:

NAME/KEY: misc_feature

; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
PCT-US03-05028-453

Query Match 90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 CUGAGUUUAAAAGGCACCC 19

|:||||:|||||||

Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 13

PCT-US03-05028-456/c

Sequence 456, Application PC/TUS0305028

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.

APPLICANT: McSwiggen, James

APPLICANT: Beigelman, Leonid

APPLICANT: Chowrira, Bharat

APPLICANT: Pavco, Pamela

APPLICANT: Fossnaugh, Kathy

APPLICANT: Jamison, Sharon

APPLICANT: Usman, Nassim

APPLICANT: Thompson, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using

FILE REFERENCE: 400/104 (MBHB 03-198)

CURRENT APPLICATION NUMBER: PCT/US03/05028

CURRENT FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/363,124

PRIOR FILING DATE: 2002-03-11

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

PRIOR APPLICATION NUMBER: US 60/386,782

PRIOR FILING DATE: 2002-06-06

PRIOR APPLICATION NUMBER: US 60/406,784

PRIOR FILING DATE: 2002-08-29

PRIOR APPLICATION NUMBER: US 60/408,378

PRIOR FILING DATE: 2002-09-05

PRIOR APPLICATION NUMBER: US 60/409,293

PRIOR FILING DATE: 2002-09-09

PRIOR APPLICATION NUMBER: US 60/440,129

PRIOR FILING DATE: 2003-01-15

NUMBER OF SEQ ID NOS: 932

SOFTWARE: PatentIn version 3.2

SEQ ID NO 456

LENGTH: 21

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

```

; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
PCT-US03-05028-456

```

```

Query Match          90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 78.9%; Pred. No. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 CUGAGUUUAAAAGGCACCC 19
    |:|:|:|:|:|:|:|:|:|
Db 19 CTGAGTTTAAAAGGCACCC 1

```

```

RESULT 14
PCT-US03-05028-459
; Sequence 459, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 459
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; FEATURE:
; NAME/KEY: misc feature

```

```

; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic mosity
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (3)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(14)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic mosity
PCT-US03-05028-459

```

```

Query Match          90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 CUGAGUUUAAAAGGCACCC 19
    |:|:|:|:|:|:|:|:|:|
Db 1 CUGAGUUUAAAAGGCACCC 19

```

```

RESULT 15
PCT-US03-05028-462/c
; Sequence 462, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06

```

```
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 462
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
PCT-US03-05028-462

Query Match          90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 78.9%; Pred. NO. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Oy      1 CUGAGUUUAAAGGCACCC 19
Db      19 CTGAGTTTAAAGGCACCC 1

Search completed: August 18, 2005, 23:33:06
Job time : 3830 secs
```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:24:18 ; Search time 610 seconds.
(without alignments)
223.664 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaggcaccm 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 7316285 seqs, 3248459403 residues

Total number of hits satisfying chosen parameters: 7811414

Minimum DB seq length: 0
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications NA:*

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq.*
- 2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq.*
- 3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq.*
- 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq.*
- 5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq.*
- 6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq.*
- 7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq.*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq.*
- 9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq.*
- 10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq.*
- 11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq.*
- 12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq.*
- 13: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq.*
- 14: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq.*
- 15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq.*
- 16: /cgn2_6/ptodata/1/pubpna/US10D_PUBCOMB.seq.*
- 17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq.*
- 18: /cgn2_6/ptodata/1/pubpna/US10F_PUBCOMB.seq.*
- 19: /cgn2_6/ptodata/1/pubpna/US10G_PUBCOMB.seq.*
- 20: /cgn2_6/ptodata/1/pubpna/US10H_PUBCOMB.seq.*
- 21: /cgn2_6/ptodata/1/pubpna/US10I_PUBCOMB.seq.*
- 22: /cgn2_6/ptodata/1/pubpna/US10J_NEW_PUB.seq.*
- 23: /cgn2_6/ptodata/1/pubpna/US11A_PUBCOMB.seq.*
- 24: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq.*
- 25: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq.*
- 26: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	ID	Description
C 1	19	90.5	19	US-10-665-951-2313
C 2	19	90.5	19	US-10-665-951-2313
C 3	19	90.5	19	US-10-665-951-2313
C 4	19	90.5	19	US-10-665-951-2313
C 5	19	90.5	21	US-10-665-951-2092
C 6	19	90.5	21	US-10-665-951-2096
C 7	19	90.5	21	US-10-665-951-2100
C 1	19	90.5	19	US-10-665-951-2313
C 2	19	90.5	19	US-10-665-951-2313
C 3	19	90.5	19	US-10-665-951-2313
C 4	19	90.5	19	US-10-665-951-2313
C 5	19	90.5	21	US-10-665-951-2092
C 6	19	90.5	21	US-10-665-951-2096
C 7	19	90.5	21	US-10-665-951-2100

C 8	19	90.5	21	19	US-10-665-951-2104	Sequence 2104, Ap
C 9	19	90.5	21	19	US-10-665-951-2149	Sequence 2149, Ap
C 10	19	90.5	21	19	US-10-665-951-2152	Sequence 2152, Ap
C 11	19	90.5	21	19	US-10-665-951-2155	Sequence 2155, Ap
C 12	19	90.5	21	19	US-10-665-951-2158	Sequence 2158, Ap
C 13	19	90.5	21	19	US-10-665-951-2161	Sequence 2161, Ap
C 14	19	90.5	21	19	US-10-665-951-2164	Sequence 2164, Ap
C 15	19	90.5	21	19	US-10-665-951-2185	Sequence 2185, Ap
C 16	19	90.5	21	19	US-10-665-951-2188	Sequence 2188, Ap
C 17	19	90.5	21	19	US-10-665-951-2218	Sequence 2218, Ap
C 18	19	90.5	21	19	US-10-665-951-2220	Sequence 2220, Ap
C 19	19	90.5	21	19	US-10-665-951-2222	Sequence 2222, Ap
C 20	19	90.5	21	19	US-10-665-951-2224	Sequence 2224, Ap
C 21	19	90.5	21	19	US-10-665-951-2281	Sequence 2281, Ap
C 22	19	90.5	21	19	US-10-665-951-2282	Sequence 2282, Ap
C 23	19	90.5	21	19	US-10-444-853A-297	Sequence 297, App
C 24	19	90.5	21	19	US-10-444-853A-301	Sequence 301, App
C 25	19	90.5	21	19	US-10-444-853A-305	Sequence 305, App
C 26	19	90.5	21	19	US-10-444-853A-345	Sequence 345, App
C 27	19	90.5	21	19	US-10-444-853A-621	Sequence 621, App
C 28	19	90.5	21	19	US-10-444-853A-622	Sequence 622, App
C 29	19	90.5	21	21	US-10-757-803-297	Sequence 297, App
C 30	19	90.5	21	21	US-10-757-803-301	Sequence 301, App
C 31	19	90.5	21	21	US-10-757-803-305	Sequence 305, App
C 32	19	90.5	21	21	US-10-757-803-345	Sequence 345, App
C 33	19	90.5	21	21	US-10-757-803-621	Sequence 621, App
C 34	19	90.5	21	21	US-10-757-803-622	Sequence 622, App
C 35	19	90.5	21	21	US-10-826-966-297	Sequence 297, App
C 36	19	90.5	21	21	US-10-826-966-301	Sequence 301, App
C 37	19	90.5	21	21	US-10-826-966-305	Sequence 305, App
C 38	19	90.5	21	21	US-10-826-966-345	Sequence 345, App
C 39	19	90.5	21	21	US-10-826-966-621	Sequence 621, App
C 40	19	90.5	21	21	US-10-826-966-622	Sequence 622, App
C 41	19	90.5	21	21	US-10-758-155-2092	Sequence 2092, Ap
C 42	19	90.5	21	21	US-10-758-155-2096	Sequence 2096, Ap
C 43	19	90.5	21	21	US-10-758-155-2100	Sequence 2100, Ap
C 44	19	90.5	21	21	US-10-758-155-2104	Sequence 2104, Ap
C 45	19	90.5	21	21	US-10-758-155-2149	Sequence 2149, Ap

ALIGNMENTS

RESULT 1

US-10-665-951-2313/c
; Sequence 2313, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580

```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: X stands for nitroindole universal base
; US-10-665-951-2313

Query Match          90.5%; Score 19; DB 19; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.2;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 2
US-10-758-155-2313/c
; Sequence 2313, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: X stands for nitroindole universal base
; US-10-758-155-2313

Query Match          90.5%; Score 19; DB 21; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.2;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 3
US-10-831-620-2313/c
; Sequence 2313, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
```


; LOCATION: (20)...(20)
; OTHER INFORMATION: X stands for nitroindole universal base
US-10-831-620-2313

Query Match 90.5%; Score 19; DB 22; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.2;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Oy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 4
US-10-844-076-2313/c
; Sequence 2313, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)...(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)...(20)
; OTHER INFORMATION: X stands for nitroindole universal base
US-10-844-076-2313

Query Match 90.5%; Score 19; DB 22; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.2;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Oy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 5

US-10-665-951-2092
; Sequence 2092, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2092
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(5)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)...(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)...(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-665-951-2092

Query Match 90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 CUGAGUUUAAAAGGCACCC 19
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 6
US-10-665-951-2096/c
; Sequence 2096, Application US/10665951

; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2096
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; US-10-665-951-2096

Query Match 90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.3;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 7
US-10-665-951-2100
; Sequence 2100, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2100
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(4)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-665-951-2100

Query Match 90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 1 CUGAGUUUAAAAGGCACCC 19


```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2155
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina sense region
;
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5' -3 attached terminal deoxyabasic moiety
;
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
;
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
;
US-10-665-951-2155

Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 100.0%; Pred.No. 4,3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps

QY      1 CUGAGUUUAAAAGGCACCC 19
        |||||
Db       1 CUGAGUUUAAAAGGCACCC 19

RESULT 12
US-10-665-951-2158/c
Sequence 2158, Application US/10665951
Publication No. US20040138163A1
GENERAL INFORMATION:
APPLICANT: Sina Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Beigelman, Leonid
APPLICANT: Pavco, Pamela
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor
TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: 400/131 (MEHB02-742-F)
CURRENT APPLICATION NUMBER: US/10/665,951
CURRENT FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: US 10/664,668
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: PCT/US 03/05022
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/399,348
PRIOR FILING DATE: 2002-07-29
PRIOR APPLICATION NUMBER: US 60/393,796
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 10/287,949
PRIOR FILING DATE: 2002-11-04
PRIOR APPLICATION NUMBER: US 10/306,747
PRIOR FILING DATE: 2002-11-27
```

```

; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2158
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; US-10-665-951-2158

Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.3;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 13
US-10-665-951-2161
; Sequence 2161, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04

```

```

; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2161
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(14)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
; US-10-665-951-2161

Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 14
US-10-665-951-2164/C
; Sequence 2164, Application US/10665951

```

```
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MEHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 2164
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-665-951-2164
```

```
Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.3;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1  CUGAGUUUAAAAGGCACCC 19
        |:|:|:|:|:|:|:|:|:|
Db      19  CTGAGTTTAAAGGCACCC 1
```

RESULT 15

```
US-10-665-951-2185
; Sequence 2185, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MEHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 2185
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-665-951-2185
```

```
Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1  CUGAGUUUAAAAGGCACCC 19
        |:|:|:|:|:|:|:|:|:|
Db      1  CUGAGUUUAAAAGGCACCC 19
```

```
Search completed: August 19, 2005, 00:12:34
Job time : 610 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 21:39:47 ; Search time 124 Seconds
(without alignments)
277.111 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaaggcaccnn 21

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 970836

Minimum DB seq length: 0
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA.*
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PTUS_COMB.seq.*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17	81.0	17	3	US-08-584-040-1494
2	17	81.0	17	3	US-08-584-040-7243
3	17	81.0	17	4	US-09-371-772B-39
4	17	81.0	17	4	US-09-685-664B-39
5	17	81.0	20	4	US-09-953-318-24
6	16	76.2	17	3	US-08-584-040-1493
7	16	76.2	17	3	US-08-584-040-7242
8	16	76.2	17	4	US-09-371-772B-38
9	16	76.2	17	4	US-09-685-664B-38
10	16	76.2	20	4	US-09-953-318-25
11	15	71.4	17	3	US-08-584-040-1492
12	15	71.4	17	3	US-08-584-040-7241
13	15	71.4	17	4	US-09-371-772B-37
14	15	71.4	17	4	US-09-685-664B-37
15	13.2	62.9	25	4	US-09-396-196G-30680
16	13.2	62.9	25	4	US-09-396-196G-30689
17	13.2	62.9	30	1	US-07-832-905B-86
18	13.2	62.9	30	2	US-08-700-757-86
19	12.8	61.0	19	4	US-09-422-978-9871
20	12.8	61.0	25	4	US-09-396-196G-44902
21	12.6	60.0	21	4	US-09-060-299-116
22	12.6	60.0	21	4	US-09-402-923A-116
23	12.4	59.0	22	4	US-09-032-438C-77
24	12.4	58.1	25	4	US-09-396-196G-18378
25	12.2	58.1	25	4	US-09-396-196G-30679
26	12.2	58.1	25	4	US-09-396-196G-106340
27	12.2	58.1	26	2	US-08-687-080-162

28	12.2	58.1	26	2	US-08-859-998-566	Sequence 566, App
29	12.2	58.1	26	3	US-09-225-928-566	Sequence 566, App
30	12.2	58.1	26	4	US-09-225-201B-566	Sequence 566, App
C 31	12.2	58.1	30	2	US-08-629-001A-68	Sequence 68, Appl
C 32	12.2	58.1	30	3	US-08-513-974B-137	Sequence 137, App
C 33	12.2	58.1	30	3	US-08-642-274D-147	Sequence 147, App
34	12	57.1	17	4	US-09-371-772B-4222	Sequence 4222, Ap
35	12	57.1	28	3	US-08-877-966B-8	Sequence 8, Appli
36	11.8	56.2	17	3	US-09-080-044-15	Sequence 15, Appl
37	11.8	56.2	17	3	US-09-531-857A-15	Sequence 15, Appl
C 38	11.8	56.2	19	4	US-09-422-978-6473	Sequence 6473, Ap
C 39	11.8	56.2	21	3	US-09-080-044-14	Sequence 14, Appl
C 40	11.8	56.2	21	3	US-09-531-857A-14	Sequence 14, Appl
C 41	11.8	56.2	22	3	US-08-771-623-3	Sequence 3, Appli
C 42	11.8	56.2	22	3	US-09-376-097-14	Sequence 14, Appl
C 43	11.8	56.2	22	4	US-08-965-492-1	Sequence 1, Appli
C 44	11.8	56.2	22	4	US-09-732-279-3	Sequence 3, Appli
C 45	11.8	56.2	25	3	US-08-771-623-27	Sequence 27, Appl

ALIGNMENTS

RESULT 1
US-08-584-040-1494
; Sequence 1494, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stichcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1494:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-584-040-1494

Query Match 81.0%; Score 17; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|||||
Db 1 CUGAGUUUAAAAGGCAC 17

RESULT 2

US-08-584-040-7243
Sequence 7243, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 218/064

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 7243:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-584-040-7243

Query Match 81.0%; Score 17; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|||||
Db 1 CUGAGUUUAAAAGGCAC 17

RESULT 3

US-09-371-772B-39

Sequence 39, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MBH00,876-J (237/198)

CURRENT APPLICATION NUMBER: US/09/371.772B

CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: Patentin version 3.0

SEQ ID NO 39

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-371-772B-39

Query Match 81.0%; Score 17; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|||||
Db 1 CUGAGUUUAAAAGGCAC 17

RESULT 4

US-09-685-664B-39

Sequence 39, Application US/09685664B

Patent No. 6818447

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate

FILE REFERENCE: MBH00-876-K (400/021)

CURRENT APPLICATION NUMBER: US/09/685,664B

CURRENT FILING DATE: 2000-10-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

PRIOR APPLICATION NUMBER: US 09/371,772

PRIOR FILING DATE: 1999-08-10

NUMBER OF SEQ ID NOS: 8231

SOFTWARE: Patentin version 3.0

SEQ ID NO 39

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-685-664B-39

Query Match 81.0%; Score 17; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|||||
Db 1 CUGAGUUUAAAAGGCAC 17


```

; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1493:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-1493

Query Match          76.2%; Score 16; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 CUGAGUUUAAAAGGCA 16
        |||||
DB       2 CUGAGUUUAAAAGGCA 17

RESULT 7
US-08-584-040-7242
; Sequence 7242, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7242:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7242

Query Match          76.2%; Score 16; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Query Match 76.2%; Score 16; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1492:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1492

Query Match 71.4%; Score 15; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CUGAGUUUAAAAGGC 17

RESULT 12
US-08-584-040-7241
; Sequence 7241, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7241:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
```

```
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7241

Query Match 71.4%; Score 15; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CUGAGUUUAAAAGGC 17

RESULT 13
US-09-371-772B-37
; Sequence 37, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 37
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-37

Query Match 71.4%; Score 15; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CUGAGUUUAAAAGGC 17

RESULT 14
US-09-685-664B-37
; Sequence 37, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 37
```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 23:33:14 ; Search time 2976 Seconds
(without alignments)
268.599 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaaggaccacnn 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 46888

Minimum DB seq length: 0
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:
1: gb_est1.*
2: gb_est2.*
3: gb_hic.*
4: gb_est3.*
5: gb_est4.*
6: gb_est5.*
7: gb_est6.*
8: gb_gss1.*
9: gb_gss2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	12.2	58.1	30	8	AZ309241 IM0013106
C 2	11.6	55.2	27	6	CD532363 26011 Ara
C 3	11.6	55.2	27	9	AG204232 Pan trogl
C 4	11.4	54.3	20	9	AG189412 Pan trogl
C 5	11.2	53.3	30	9	CC887301 SALK 1499
C 6	10.8	51.4	30	8	AZ804304 2M0065M14
C 7	10.6	50.5	20	8	AZ864535 2M0174J12
C 8	10.6	50.5	25	8	AZ397442 1M0162K19
C 9	10.6	50.5	25	8	AZ792292 2M0043H11
C 10	10.6	50.5	28	9	AJ588176 Arabidops
C 11	10.4	49.5	23	9	AL464277 T. brucei
C 12	10.4	49.5	24	1	AJ258068 AU580868
C 13	10.4	49.5	24	8	AZ660125 1M0538F04
C 14	10.4	49.5	29	8	AZ457829 1M0261C20
C 15	10.4	49.5	29	8	AZ813693 2M0081P03
C 16	10.2	48.6	19	1	A1678558 tu83h07.x
C 17	10.2	48.6	19	8	AZ428450 1M0210024
C 18	10.2	48.6	20	8	AZ368997 1M0119B20
C 19	10.2	48.6	22	9	AL452318 T. brucei
C 20	10.2	48.6	23	9	CT793275 SALK 0126
C 21	10.2	48.6	25	8	AZ583031 1M0376C15
C 22	10.2	48.6	25	8	AZ785568 2M0029K02
C 23	10.2	48.6	25	9	HSWC37C02
C 24	10.2	48.6	26	8	AZ445641 1M0241L05

C 25	10.2	48.6	30	1	AL585483
C 26	10	47.6	23	8	AZ387817
C 27	10	47.6	23	8	AZ584523
C 28	10	47.6	25	1	AU254095
C 29	10	47.6	25	8	AZ789794
C 30	10	47.6	26	8	AZ783417
C 31	10	47.6	27	7	D19150
C 32	10	47.6	27	8	AZ470253
C 33	10	47.6	28	8	AZ535595
C 34	10	47.6	29	8	AZ640466
C 35	10	47.6	29	8	AZ966795
C 36	10	47.6	30	9	TA7F10Q
C 37	9.8	46.7	19	8	AZ410166
C 38	9.8	46.7	19	8	AZ659603
C 39	9.8	46.7	20	1	AU254453
C 40	9.8	46.7	21	7	CO789498
C 41	9.8	46.7	22	8	AZ424233
C 42	9.8	46.7	23	8	AZ796147
C 43	9.8	46.7	25	1	AU007217
C 44	9.8	46.7	26	4	BM400078
C 45	9.8	46.7	26	8	AZ514488

ALIGNMENTS

RESULT 1
AZ309241/c
LOCUS
DEFINITION
AZ309241
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

AZ309241
1M0013106F Mouse 10kb plasmid UUC1M library Mus musculus genomic
Clone UUC1M0013106 F, genomic survey sequence.

AZ309241
GI:10350030

GSS.

Mus musculus (house mouse)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 30)

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,

Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von

Niederhausern, A. and Wright, D., Weiss, R.,

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0013 row: 1 column: 06

Seq primer: CGTTGTAACACGCGCCAGT

Class: plasmid ends

High quality sequence stop: 30.

Location/Qualifiers

1..30

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clones="UUC1M0013106"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUC1M library"

/note="Vector: PWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA


```

REFERENCE
AUTHORS      Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,
              Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.
TITLE        BAC end sequences of Library RP-43
REFERENCE
AUTHORS      Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,
              Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.
TITLE        Direct Submission
JOURNAL      Submitted (07-JAN-2002) Hong-Seog Park, Korea Research Institute of
              Bioscience and Biotechnology (KRIBB), Genome Research Center (GRC);
              52, Oun-dong, Yusong-gu, Daejeon 305-333, Korea
              (E-mail:redstone@kribb.re.kr, URL:http://pds.grc.kribb.re.kr/,
              Tel:82-42-866-7181, Fax:82-42-860-4409)
COMMENT      Clones are derived from the chimpanzee BAC library RP-43 This BAC
              end was generated during the R&D process and may have higher chance
              of clone tracking errors.
PRIMERS
Sequencing: TJ
LIBRARY
Vector       : pBACe3.6
R.Site 1     : EcoRI
R.Site 2     : EcoRI
FEATURES
source      Location/Qualifiers
              1..20
              /organism="Pan troglodytes"
              /mol_type="genomic DNA"
              /db_xref="taxon:9598"
              /clone="RP43-063018.TJ"
              /sex="male"
              /cell_type="lymphocytes"
              /clone_lib="RP-43 Chimpanzee Male BAC Library"
ORIGIN
Query Match      54.3%; Score 11.4; DB 9; Length 20;
Best Local Similarity 61.5%; Pred. No. 5.3e+05;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      1 CUGAGUUUAAAAG 13
        ||| :|||||
        2 CTGACTTTAAAAG 14
        ||| :|||||

RESULT 5
CC887301
LOCUS      CC887301.1 GI:33363657
DEFINITION Arabidopsis thaliana genomic clone SALK_149938.31.65.x, genomic
              survey sequence.
ACCESSION      CC887301
VERSION        CC887301.1
KEYWORDS       Arabidopsis thaliana (thale cress)
SOURCE         Arabidopsis thaliana
ORGANISM       Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
              Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
              rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
AUTHORS      Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,
              Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
              Shinn,P., Zimmerman,J. and Ecker,J.R.
TITLE        A Sequence-Indexed Library of Insertion Mutations in the
              Arabidopsis Genome
JOURNAL      Unpublished (2001)
COMMENT      Contact: Joseph R. Ecker
              Salk Institute Genomic Analysis Laboratory (SIGnAL)
              The Salk Institute for Biological Studies
              10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
              Tel: 858 453 4100 x1752
              Fax: 858 558 6379
              Email: ecker@salk.edu
              This is single pass sequence recovered from the left border of

```

```

TDNA.
Class: TDNA tagged.
Location/Qualifiers
              1..30
              /organism="Arabidopsis thaliana"
              /mol_type="genomic DNA"
              /ecotype="Col-0"
              /db_xref="taxon:3702"
              /clone="SALK_149938.31.65.x"
              /clone_lib="Arabidopsis thaliana TDNA insertion lines"
              /note="PCR was performed on Arabidopsis thaliana lines
              each of which contains one or more TDNA insertion
              elements. The resultant fragment for each line was
              directly sequenced to determine the genomic sequence at
              the site of insertion. Details of the protocols used can
              be found at http://signal.salk.edu/tdna_protocols.html"
ORIGIN
Query Match      53.3%; Score 11.2; DB 9; Length 30;
Best Local Similarity 68.8%; Pred. No. 6.8e+05;
Matches 11; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy      1 CUGAGUUUAAAAGGCA 16
        |||| :|||||
        2 CGGAGTATATAAGCAA 17
        |||| :|||||

RESULT 6
AZ804304/c
LOCUS      AZ804304.1
DEFINITION 2M0065M14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
              clone UUGC2M0065M14 F, genomic survey sequence.
ACCESSION      AZ804304
VERSION        AZ804304.1
KEYWORDS       GSS.
SOURCE         Mus musculus (house mouse)
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
              1 (bases 1 to 30)
              Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
              Ielam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
              Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
              Niederhausern,A. and Wright,D., Weiss,R.
              Mouse whole genome scaffolding with paired end reads from 10kb
              plasmid inserts
              Unpublished (2000)
              Contact: Robert B. Weiss
              University of Utah Genome Center
              University of Utah
              Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
              84112, USA
              Tel: 801 585 5606
              Fax: 801 585 7177
              Email: ddunn@genetics.utah.edu
              Insert Length: 10000 Std Error: 0.00
              Plate: 0065 row: M column: 14
              Seq primer: CGTTGTAAACACGCGCCAGT
              Class: plasmid ends
              High quality sequence stop: 30.
FEATURES
source      Location/Qualifiers
              1..30
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /strain="C57BL/6J"
              /db_xref="taxon:10090"
              /clone="UUGC2M0065M14"
              /sex="Male"
              /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
              /clone_lib="Mouse 10kb plasmid UUGC1M library"
              /note="Vector: PWD42nv; Purified genomic DNA from M.
              musculus C57BL/6J (male) was obtained from the Jackson
              Laboratory Mouse DNA Resource

```

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydronically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pW42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN

Query Match 51.4%; Score 10.8; DB 8; Length 30;
Best Local Similarity 64.3%; Pred. No. 1.1e+06;
Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2 UGAGUUUAAAGGC 15
: : : : :
Db 28 TGAGTCTCAAAGGC 15

RESULT 7

AZ864535/c
LOCUS 20174J12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC2M0174J12 F, genomic survey sequence.

ACCESSION AZ864535
VERSION 1
KEYWORDS GI:130633933
SOURCE GSS.

Mus musculus (house mouse)

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0174 row: J column: 12
Seq primer: CGTGTAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 20.
Location/Qualifiers
1. .20

FEATURES

source

1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0174J12"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydronically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pW42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN

Query Match 50.5%; Score 10.6; DB 8; Length 20;
Best Local Similarity 64.7%; Pred. No. 1.3e+06;
Matches 11; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 3 GAGUUUAAAGGCACCC 19
: : : : :
Db 20 GTGTTGATAGGCCCCC 4

RESULT 8

AZ397442/c
LOCUS 1M0162K19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0162K19 F, genomic survey sequence.

ACCESSION AZ397442
VERSION 1
KEYWORDS GI:10512514
SOURCE GSS.

Mus musculus (house mouse)

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0162 row: K column: 19
Seq primer: CGTGTAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 25.
Location/Qualifiers
1. .25

FEATURES

source

1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0162K19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN

Query Match 50.5%; Score 10.6; DB 8; Length 25;
Best Local Similarity 52.9%; Pred. No. 1.4e+06;
Matches 9; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 2 UGAGUUUAAAAGGCACC 18
:|||||
Db 24 TGGGTTTAAAGAGAGC 8

RESULT 9

AZ792292
LOCUS AZ792292 25 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0043H11R Mouse 10kb plasmid UUC1M library Mus musculus genomic clone UUCG2M0043H11 R, genomic survey sequence.

ACCESSION AZ792292.1 GI:12936073

VERSION AZ792292

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 25)

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Ielam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von Niederhauser, A., and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL

Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: cdunne@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0043 row: H column: 11

Seq primer: CACACAGGAACAGCTATGACC

Class: plasmid ends

High quality sequence stop: 25.

Location/Qualifiers

FEATURES

source

1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG2M0043H11"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN

Query Match 50.5%; Score 10.6; DB 8; Length 25;
Best Local Similarity 52.9%; Pred. No. 1.4e+06;
Matches 9; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 2 UGAGUUUAAAAGGCACC 18
:|||||
Db 3 TGGGTTTATAGACACC 19

RESULT 10

AJ588176
LOCUS AJ588176 28 bp DNA linear GSS 15-JAN-2004
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 527H09, genomic survey sequence.

ACCESSION AJ588176.1 GI:37937800

VERSION AJ588176

KEYWORDS GSS; left border; T-DNA flanking sequence.

SOURCE Arabidopsis thaliana (thale cress)

ORGANISM Arabidopsis thaliana

REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids. 1

AUTHORS

Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelleterier, G., Lepiniec, L., Caboche, M., and Lecharny, A.

TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites

JOURNAL

EMBO Rep. 3 (12), 1152-1157 (2002)

MEDLINE

2263535

PUBMED

12446565

REFERENCE

2 (bases 1 to 28)

AUTHORS

Balzerque, S.

TITLE

Direct Submision

JOURNAL

Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue

COMMENT

Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment (s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES

Location/Qualifiers

1. .28

/organism="Arabidopsis thaliana"

/mol_type="genomic DNA"

/cultivar="Wassillewskija"

/db_xref="taxon:3702"

/clone="527H09"

/clone_lib="Arabidopsis thaliana T-DNA insertion lines"


```

/db_xref="taxon:10090"
/clone="UUGC1M0538F04"
/sex="Male"
/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMDA2 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

ORIGIN

```

Query Match      49.5%; Score 10.4; DB 8; Length 24;
Best Local Similarity 58.3%; Pred. No. 1.7e+06;
Matches          7; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy      2 UGAGUUUAAAG 13
       :|:::|||||
Db      22 TGTGTTTAAAG 11

```

```

RESULT 14
A2457829/c
LOCUS      A2457829      29 bp      DNA      linear      GSS 04-OCT-2000
DEFINITION clone UUGC1M0261C20 F, genomic survey sequence.
ACCESSION  A2457829
VERSION     A2457829.1 GI:10615954
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 29)
AUTHORS    Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Irlam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D., Weiss,R.
TITLE      Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
JOURNAL     Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0261 row: C column: 20
            Seq primer: CGTTGTAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 29.
FEATURES    Location/Qualifiers
             1..29
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /strain="C57BL/6J"

```

```

/db_xref="taxon:10090"
/clone="UUGC1M0261C20"
/sex="Male"
/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMDA2 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

ORIGIN

```

Query Match      49.5%; Score 10.4; DB 8; Length 29;
Best Local Similarity 58.3%; Pred. No. 1.7e+06;
Matches          7; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy      2 UGAGUUUAAAG 13
       :|:::|||||
Db      20 TCAGTTTAAAG 9

```

```

RESULT 15
A2813693
LOCUS      A2813693      29 bp      DNA      linear      GSS 20-FEB-2001
DEFINITION clone UUGC2M0081P03 F, genomic survey sequence.
ACCESSION  A2813693
VERSION     A2813693.1 GI:12983601
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 29)
AUTHORS    Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Irlam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D., Weiss,R.
TITLE      Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
JOURNAL     Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0081 row: P column: 03
            Seq primer: CGTTGTAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 29.
FEATURES    Location/Qualifiers
             1..29
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /strain="C57BL/6J"

```

```
/db xref="taxon:10090"
/clone="UUGC2M0081P03"
/sex="Male"
/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/vector="PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
```

ORIGIN

```
Query Match          49.5%; Score 10.4; DB 8; Length 29;
Best Local Similarity 58.3%; Pred. No. 1.7e+06;
Matches 7; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1 CUGAGUUUUAAAA 12
        |:|:|:|:|:|:|
Db       12 CTGACTTTAAAA 23
```

Search completed: August 19, 2005, 01:37:26
Job time : 2980 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:25:38 ; Search time 416 Seconds
(without alignments)
298.833 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaagaccacm 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 3522762

Minimum DB seq length: 0

Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N Geneseq_16Dec04.*
1: Geneseq_1980s.*
2: Geneseq_1990s.*
3: Geneseq_2000s.*
4: Geneseq_2001as.*
5: Geneseq_2001bs.*
6: Geneseq_2002as.*
7: Geneseq_2002bs.*
8: Geneseq_2003as.*
9: Geneseq_2003bs.*
10: Geneseq_2003cs.*
11: Geneseq_2003ds.*
12: Geneseq_2004as.*
13: Geneseq_2004bs.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19	90.5	21	9 ADA13968	ADA13968 Short int
C 2	19	90.5	21	9 ADA13964	ADA13964 Short int
C 3	19	90.5	21	9 ADA13613	ADA13613 Short int
C 4	19	90.5	21	9 ADA13960	ADA13960 Short int
C 5	19	90.5	21	10 ADF37903	Adf37903 Human VEG
C 6	19	90.5	21	10 ADF37751	Adf37751 Human VEG
C 7	19	90.5	21	10 ADF37745	Adf37745 Human VEG
C 8	19	90.5	21	10 ADF37775	Adf37775 Human VEG
C 9	19	90.5	21	10 ADF37899	Adf37899 Human VEG
C 10	19	90.5	21	10 ADF37907	Adf37907 Human VEG
C 11	19	90.5	21	10 ADF37736	Adf37736 Human VEG
C 12	19	90.5	21	10 ADF37895	Adf37895 Human VEG
C 13	19	90.5	21	10 ADF37739	Adf37739 Human VEG
C 14	19	90.5	21	10 ADF39836	Adg29836 FLT1-targ
C 15	19	90.5	21	10 ADG29884	Adg29884 FLT1-targ
C 16	19	90.5	21	10 ADG29890	Adg29890 FLT1-targ
C 17	19	90.5	21	10 ADG29832	Adg29832 FLT1-targ
C 18	19	90.5	21	10 ADG29896	Adg29896 FLT1-targ
C 19	19	90.5	21	10 ADG29828	Adg29828 FLT1-targ
C 20	19	90.5	21	10 ADG29881	Adg29881 FLT1-targ

C 21	19	90.5	21	10 ADG29920	Adg29920 FLT1-targ
C 22	19	90.5	21	10 ADG29824	Adg29824 FLT1-targ
C 23	19	90.5	23	10 ADF37772	Adf37772 Human VEG
C 24	19	90.5	23	10 ADF37812	Adf37812 Human VEG
C 25	19	90.5	23	10 ADF37742	Adf37742 Human VEG
C 26	19	90.5	23	10 ADF37748	Adf37748 Human VEG
C 27	19	90.5	23	10 ADF37748	Adf37748 Human VEG
C 28	19	90.5	23	10 ADG29490	Adg29490 FLT1-targ
C 29	19	90.5	23	10 ADG29893	Adg29893 FLT1-targ
C 30	19	90.5	23	10 ADG29917	Adg29917 FLT1-targ
C 31	17	81.0	17	2 AAX74493	Aax74493 Mouse flt
C 32	17	81.0	17	2 AAX68744	Aax68744 Human flt
C 33	17	81.0	20	8 ACC86729	Acc86729 Human VEG
C 34	16	76.2	17	2 AAX68743	Aax68743 Human flt
C 35	16	76.2	17	2 AAX74492	Aax74492 Mouse flt
C 36	16	76.2	20	8 ACC86730	Acc86730 Human VEG
C 37	15	71.4	17	2 AAX68742	Aax68742 Human flt
C 38	15	71.4	17	2 AAX74491	Aax74491 Mouse flt
C 39	14.2	67.6	22	3 AAZ87380	Aaz87380 Human thr
C 40	14.2	67.6	24	3 AAZ87381	Aaz87381 Human thr
C 41	13.8	65.7	28	2 AAX28169	Aax28169 PCR prime
C 42	13.2	62.9	30	2 AAT58464	Aat58464 PEPC gen
C 43	13.2	62.9	30	2 AAV82574	Aav82574 PCR prime
C 44	13	61.9	19	10 ADF35731	Adf35731 Human VEG
C 45	13	61.9	19	10 ADF36158	Adf36158 Human VEG

ALIGNMENTS

RESULT 1

ADA13968/c
ID ADA13968 standard; RNA; 21 BP.

XX AC ADA13968;

DT 20-NOV-2003 (first entry)

DE Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:305.

XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.

XX Synthetic.

XX WO2003070918-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005346.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 06-JUN-2002; 2002US-0386782P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokler V, Jamison S;

```
DR WPI; 2003-689785/65.
XX
XX New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
XX Example 4; Page 142; 204pp; English.
PS
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. siNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytosstatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
SQ Query Match 90.5%; Score 19; DB 9; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 2
ID ADA13964/c
XX ADA13964 standard; RNA; 21 BP.
XX
XX ADA13964;
XX
XX 20-NOV-2003 (first entry)
XX
XX Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:301.
XX
XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytosstatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX
```

```
OS Synthetic.
XX
XX W0203070918-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005346.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX McSwiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
XX Morrissey D, Fosnaugh K, Mokler V, Jamison S;
PI WPI; 2003-689785/65.
XX
XX New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
XX Example 4; Page 142; 204pp; English.
PS
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. siNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytosstatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
SQ Query Match 90.5%; Score 19; DB 9; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 3
```


the siRNA molecule comprises no ribonucleotides and each strand of the double-stranded siRNA comprises about 21 nucleotides. Also described: (1) a siRNA molecule that inhibits expression of target RNA; (2) a siRNA molecule that inhibits replication of a virus and optionally does not require presence of a ribonucleotide for inhibition; (3) a siRNA molecule that inhibits expression of a target gene and does not require presence of a ribonucleotide for inhibition; (4) a siRNA molecule that inhibits expression of a target gene by mediating RNA interference; and (5) a method for modulating expression of a gene in a cell using siRNA molecules. siRNA's can have virucide, anti-HIV, hepatotropic, antiinflammatory, plant antiviral, vasotropic, neuroprotective, cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic and endocrine activities. The siRNA's are useful for downregulating expression of target genes, inhibiting expression of target RNA, and inhibiting replication of a virus. siRNA molecules can be used: (a) for therapy of any disorder that responds to modulation of gene expression, especially animal and plant viral infections, specifically hepatitis B or C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory syncytial or influenza viruses, and also many other diseases such as restenosis, neurodegeneration, cancers, and cardiovascular, neurological, prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial, endocrine or reproductive diseases; and (b) for diagnosis, target validation, genomic discovery, genetic engineering, pharmacogenomics and analysis of gene function. Chemical modification of siRNA molecules improves interfering activity; stability; cellular uptake; binding affinity and/or mediates increased polymerase activity. siRNA may be designed to target many related genes containing a conserved sequence. The present sequence represents a siRNA oligonucleotide sequence, which is used in the exemplification of the present invention.

Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;

Query Match 90.5%; Score 19; DB 9; Length 21;

Best Local Similarity 100.0%; Pred. No. 1.8; Length 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CUGAGUUUAAAAGGCACCC 19

DB 1 CUGAGUUUAAAAGGCACCC 19

RESULT 5

AD37903
ID ADF37903 standard; RNA; 21 BP.

XX ADF37903;

XX 12-FEB-2004 (first entry)

XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2100.

XX double-stranded short interfering nucleic acid;

XX short interfering nucleic acid; siNA; downregulation;
XX vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
XX cytoskeletal; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
XX nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
XX diabetic retinopathy; macular degeneration; neovascular glaucoma;
XX arthritis; psoriasis; endometriosis; angiofibroma;
XX polycystic kidney disease; ss.

XX Synthetic.

XX Homo sapiens.

XX WO2003070910-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005022.

XX 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 29-MAY-2002; 2002WO-US017674.

PR 06-JUN-2002; 2002US-0386782P.

PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.

XX McSwiggen J, Beigelman L, Pavco P;

XX WPI; 2003-679876/64.

XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.

XX Example 3; SEQ ID NO 2100; 207pp; English.

XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.

XX Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;

Query Match 90.5%; Score 19; DB 10; Length 21;

Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CUGAGUUUAAAAGGCACCC 19

DB 1 CUGAGUUUAAAAGGCACCC 19

RESULT 6

AD37751/c

ID ADF37751 standard; RNA; 21 BP.

XX ADF37751;

XX 12-FEB-2004 (first entry)

XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2164.

XX double-stranded short interfering nucleic acid;

XX short interfering nucleic acid; siNA; downregulation;
XX vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
XX cytoskeletal; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
XX nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
XX diabetic retinopathy; macular degeneration; neovascular glaucoma;
XX arthritis; psoriasis; endometriosis; angiofibroma;
XX polycystic kidney disease; ss.

XX Synthetic.

OS Homo sapiens.

XX

PN WO2003070910-A2.
XX 28-AUG-2003.
XX 20-FEB-2003; 2003WO-US005022.
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
PA Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX Example 3; SEQ ID NO 2164; 207pp; English.
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
XX exemplification of the present invention.
XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
SQ Query Match 90.5%; Score 19; DB 10; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1 CUGAGUUUAAAGGCACCC 19
DB 19 CTGAGTTTAAAGGCACCC 1
RESULT 7
ADF37745/c
ID ADF37745 standard; RNA; 21 BP.
XX ADF37745;
AC ADF37745;
XX 12-FEB-2004 (first entry)
DT Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2158.
DE double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; downregulation;
KW ADF37775/c
RESULT 8
ADF37775/c

KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytosolic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX Synthetic.
OS Homo sapiens.
XX WO2003070910-A2.
XX 28-AUG-2003.
XX 20-FEB-2003; 2003WO-US005022.
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
PA Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX Example 3; SEQ ID NO 2158; 207pp; English.
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
XX exemplification of the present invention.
XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
SQ Query Match 90.5%; Score 19; DB 10; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1 CUGAGUUUAAAGGCACCC 19
DB 19 CTGAGTTTAAAGGCACCC 1
RESULT 7
ADF37745/c
ID ADF37745 standard; RNA; 21 BP.
XX ADF37745;
AC ADF37745;
XX 12-FEB-2004 (first entry)
DT Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2158.
DE double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; downregulation;
KW ADF37775/c
RESULT 8
ADF37775/c

ID ADF37775 standard; RNA; 21 BP.
XX ADF37775;
XX
XX
DT 12-FEB-2004 (first entry)
XX
XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2188.
XX
XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytoskeletal; antiangiogenic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO2003070910-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005022.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 2188; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antiarthritic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
Query Match 90.5%; Score 19; DB 10; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1 CUGAGUUUAAAAGCACCC 19
DB 19 CTGAGTTTAAAAGCACCC 1
RESULT 9
ADF37899/c
ID ADF37899 standard; RNA; 21 BP.
XX
XX ADF37899;
DT 12-FEB-2004 (first entry)
XX
XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2096.
XX
XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytoskeletal; antiangiogenic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO2003070910-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005022.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 2096; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antiarthritic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,

CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.

XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 90.5%; Score 19; DB 10; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19

Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 10

ADF37907/C

ID ADF37907 standard; RNA; 21 BP.

XX ADF37907;

DT 12-FEB-2004 (first entry)

DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2104.

XX double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cytosstatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.

XX Synthetic.

OS Homo sapiens.

XX WO2003070910-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005022.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 29-MAY-2002; 2002WO-US017674.

XX 06-JUN-2002; 2002US-0386782P.

XX 03-JUL-2002; 2002US-0393796P.

XX 29-JUL-2002; 2002US-0399348P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX 04-NOV-2002; 2002US-00287949.

XX 27-NOV-2002; 2002US-00306747.

XX 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Pavco P;

XX WPI, 2003-679876/64.

XX New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.

XX Example 3; SEQ ID NO 2104; 207pp; English.

CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.

XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 90.5%; Score 19; DB 10; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19

Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 11

ADF37736

ID ADF37736 standard; RNA; 21 BP.

XX ADF37736;

DT 12-FEB-2004 (first entry)

DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2149.

XX double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cytosstatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.

XX Synthetic.

OS Homo sapiens.

XX WO2003070910-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005022.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 29-MAY-2002; 2002WO-US017674.

XX 06-JUN-2002; 2002US-0386782P.

XX 03-JUL-2002; 2002US-0393796P.

XX 29-JUL-2002; 2002US-0399348P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 04-NOV-2002; 2002US-00287949.

XX 27-NOV-2002; 2002US-00306747.

XX 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Pavco P;

DR WPI; 2003-679876/64.
 XX New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 XX
 XX Example 3; SEQ ID NO 2149; 207pp; English.
 PS
 XX The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;
 Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.8;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUAAAAGGCACCC 19
 DB 1 CUGAGUUUAAAAGGCACCC 19
 RESULT 12
 ADF37895
 ID ADF37895 standard; RNA; 21 BP.
 XX
 AC ADF37895;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2092.
 XX
 KW double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cyostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.
 XX
 XX Synthetic.
 OS
 OS Homo sapiens.
 PN WO2003070910-A2.
 XX
 PD 28-AUG-2003.
 XX
 PF 20-FEB-2003; 2003WO-US005022.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 29-MAY-2002; 2002WO-US017674.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 03-JUL-2002; 2002US-0393796P.
 PR 29-JUL-2002; 2002US-0399348P.
 PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 04-NOV-2002; 2002US-00287949.
 PR 21-NOV-2002; 2002US-00306747.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Meswiggen J, Beigelman L, Pavco P;
 PI WPI; 2003-679876/64.
 DR
 XX New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 XX
 XX Example 3; SEQ ID NO 2092; 207pp; English.
 PS
 XX The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;
 Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.8;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUAAAAGGCACCC 19
 DB 1 CUGAGUUUAAAAGGCACCC 19
 RESULT 13
 ADF37739/c
 ID ADF37739 standard; RNA; 21 BP.
 XX
 AC ADF37739;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2152.
 XX
 KW double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cyostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.
 XX
 XX Synthetic.
 OS
 OS Homo sapiens.
 XX
 PN WO2003070910-A2.
 XX
 PD 28-AUG-2003.

```

XX PF 20-FEB-2003; 2003WO-US005022.
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 29-MAY-2002; 2002WO-US017674.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 03-JUL-2002; 2002US-0393796P.
XX PR 29-JUL-2002; 2002US-0399348P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 04-NOV-2002; 2002US-00287949.
XX PR 27-NOV-2002; 2002US-00306747.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX DR New double-stranded interfering nucleic acid, useful e.g. for treatment
XX PT and diagnosis of cancer, downregulates the vascular endothelial growth
XX PT factor receptor gene.
XX PT
XX PS Example 3; SEQ ID NO 2152; 207pp; English.
XX CC The present invention describes a double-stranded short interfering
XX CC nucleic acid (siNA) that downregulates expression of the vascular
XX CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
XX CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
XX CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
XX CC that express siNA; and (5) single-stranded siNA with similar properties.
XX CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
XX CC ophthalmological, antiarthritic, antipsoriatic, antineoplastic and
XX CC gynaecological activities. The siNA are useful for modulating
XX CC (downregulating) the expression of VEGFR genes. The siNA are potentially
XX CC useful for treating a wide range of angiogenesis-associated conditions,
XX CC particularly cancers, diabetic retinopathy, macular degeneration,
XX CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiodysplasia,
XX CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
XX CC drug screening, target identification and validation, genetic
XX CC engineering, studying gene function, and also for gene mapping (e.g. of
XX CC single-nucleotide polymorphisms). The present sequence is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
Query Match 90.5%; Score 19; DB 10; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1
RESULT 14
ADG29836/c
ID ADG29836 standard; RNA; 21 BP.
XX AC ADG29836;
XX AC
XX DT 26-FEB-2004 (first entry)
XX DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 402.
XX KW double-stranded short interfering nucleic acid; siNA;
XX KW antiarteriosclerotic; neuroprotective; nontropic; antiparkinsonian;
XX KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
XX KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
XX KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
XX OS Unidentified.
XX OS Synthetic.
XX PN WO2003074654-A2.
XX PD 12-SEP-2003.
XX PF 20-FEB-2003; 2003WO-US005028.
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
XX PI Jamison S, Usman N, Thompson J;
XX DR WPI; 2003-731676/69.
XX CC New double-stranded short interfering nucleic acid molecule, useful for
XX CC down-regulating the expression of an endogenous mammalian target gene or
XX CC for treating diseases that respond to modulation of gene expression or
XX CC activity.
XX CC Example 24; SEQ ID NO 402; 593pp; English.
XX CC The invention relates to a double-stranded short interfering nucleic acid
XX CC (siNA) molecule that down-regulates expression of an endogenous mammalian
XX CC target gene comprising one or more chemical modifications and each strand
XX CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
XX CC the invention demonstrates antiarteriosclerotic, neuroprotective,
XX CC nontropic, antiparkinsonian and anticonvulsant activities and may be
XX CC useful for down-regulating the expression of an endogenous mammalian
XX CC target gene and therefore in the treatment of any disease or condition
XX CC that responds to modulation of gene expression or activity in a cell,
XX CC tissue or organism. The disease or condition may include pulmonary
XX CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
XX CC Parkinson's disease, epilepsy, dementia, huntington's disease or
XX CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
XX CC gene therapy applications. The current sequence is that of the siNA DNA-
XX CC RNA hybrid of the invention.
XX SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
Query Match 90.5%; Score 19; DB 10; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1
RESULT 15
ADG29884/c
ID ADG29884 standard; RNA; 21 BP.
XX AC ADG29884;
XX AC
XX DT 26-FEB-2004 (first entry)
XX DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 450.
XX KW double-stranded short interfering nucleic acid; siNA;
XX KW antiarteriosclerotic; neuroprotective; nontropic; antiparkinsonian;
XX KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
XX KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
XX KW amyotrophic lateral sclerosis; gene therapy; epilepsy; dementia; huntington's;

```

KW anyotropic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
 XX Unidentified.
 OS Synthetic.
 XX WO2003074654-A2.
 PN 12-SEP-2003.
 XX 20-FEB-2003; 2003WO-US005028.
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA Mcswiggen J, Beigelman L, Chowira B, Pavco P, Fosnaugh K;
 PI Jamison S, Usman N, Thompson J;
 PI WPI; 2003-731676/69.
 DR XX New double-stranded short interfering nucleic acid molecule, useful for
 PT down-regulating the expression of an endogenous mammalian target gene or
 PT for treating diseases that respond to modulation of gene expression or
 PT activity.
 XX Example 24; SEQ ID NO 450; 593pp; English.
 PS The invention relates to a double-stranded short interfering nucleic acid
 XX (siNA) molecule that down-regulates expression of an endogenous mammalian
 CC target gene comprising one or more chemical modifications and each strand
 CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
 CC the invention demonstrates antiarteriosclerotic, neuroprotective,
 CC neurotropic, antiparkinsonian and anticonvulsant activities and may be
 CC useful for down-regulating the expression of an endogenous mammalian
 CC target gene and therefore in the treatment of any disease or condition
 CC that responds to modulation of gene expression or activity in a cell,
 CC tissue or organism. The disease or condition may include pulmonary
 CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
 CC Parkinson's disease, epilepsy, dementia, Huntington's disease or
 CC anyotropic lateral sclerosis. Furthermore, the siNA may be utilised for
 CC gene therapy applications. The current sequence is that of the siNA DNA-
 CC RNA hybrid of the invention.
 XX SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
 Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUAAAAGGCACC 19
 Db 19 CTGAGTTTAAAGGCACC 1

Search completed: August 19, 2005, 00:19:44
 Job time : 418 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:27:38 ; Search time 1660 Seconds
(without alignments)
612.988 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaaggaccacm 21

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 4708233 seqs, 24227607955 residues

Total number of hits satisfying chosen parameters: 1437254

Minimum DB seq length: 0

Maximum DB seq length: 30

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl.*

1: gb_ba.*

2: gb_hcg.*

3: gb_in.*

4: gb_on.*

5: gb_ov.*

6: gb_pat.*

7: gb_ph.*

8: gb_pl.*

9: gb_pr.*

10: gb_ro.*

11: gb_sts.*

12: gb_sy.*

13: gb_un.*

14: gb_vi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	17	81.0	17	6	AR186006 Sequence
2	17	81.0	17	6	AR191755 Sequence
3	17	81.0	17	6	AR322637 Sequence
C 4	17	81.0	20	6	AR489901 Sequence
5	16	76.2	17	6	AR186005 Sequence
6	16	76.2	17	6	AR191754 Sequence
7	16	76.2	17	6	AR322636 Sequence
C 8	16	76.2	20	6	AR489902 Sequence
9	15	71.4	17	6	AR186004 Sequence
10	15	71.4	17	6	AR191753 Sequence
11	15	71.4	17	6	AR322635 Sequence
C 12	14.2	67.6	22	6	BD233486 Novel hum
13	14.2	67.6	24	6	BD233487 Novel hum
C 14	13.8	65.7	21	4	AJ000790 Sus scrofa
C 15	13.8	65.7	28	6	A98496 Sequence 6
C 16	13.2	62.9	30	6	AR063801 Sequence 6
17	13.2	62.9	30	6	I30164 Sequence 86
C 18	12.8	61.0	19	6	AR298136 Sequence
19	12.8	61.0	21	6	CQ831028 Sequence

20	12.8	61.0	21	6	CQ831032 Sequence
21	12.8	61.0	21	6	CQ831033 Sequence
22	12.8	61.0	29	6	BD253259 Regulation
23	12.8	61.0	29	6	BD257882 Regulation
24	12.6	60.0	21	6	AR305162 Sequence
25	12.6	60.0	21	6	AR309266 Sequence
26	12.6	60.0	21	6	BD106073 Novel LDL
C 27	12.4	59.0	22	6	AR490983 Sequence
28	12.4	59.0	22	6	AX189449 Sequence
29	12.4	59.0	25	6	CQ866235 Sequence
C 30	12.2	58.1	20	6	AX296022 Sequence
C 31	12.2	58.1	21	6	BD227361 Secreted
32	12.2	58.1	24	6	CQ767557 Sequence
C 33	12.2	58.1	24	6	AX291389 Sequence
C 34	12.2	58.1	25	6	AX610941 Sequence
C 35	12.2	58.1	26	6	AR079371 Sequence
36	12.2	58.1	26	6	AR090446 Sequence
37	12.2	58.1	26	6	AR197481 Sequence
38	12.2	58.1	26	6	AR259635 Sequence
39	12.2	58.1	26	6	AX391910 Sequence
C 40	12.2	58.1	30	6	AR028219 Sequence
C 41	12.2	58.1	30	6	AR109713 Sequence
C 42	12.2	58.1	30	6	AR138622 Sequence
43	12	57.1	17	6	AR326820 Sequence
44	12	57.1	25	6	AX610004 Sequence
45	12	57.1	28	6	AR234725 Sequence

ALIGNMENTS

RESULT 1	AR186006	Sequence 1494 from patent US 6346398.	17 bp	DNA	linear	PAT 20-APR-2002
LOCUS	AR186006	Sequence 1494 from patent US 6346398.				
DEFINITION	AR186006	Sequence 1494 from patent US 6346398.				
ACCESSION	AR186006	Sequence 1494 from patent US 6346398.				
VERSION	AR186006.1	GI:20231971				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	1 (bases 1 to 17)					
AUTHORS	Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.					
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor					
JOURNAL	Patent: US 6346398-A 1494 12-FEB-2002;					
FEATURES	Location/Qualifiers					
source	1..17					
	/organism="unknown"					
	/mol_type="unassigned DNA"					

ORIGIN	Query Match	81.0%;	Score 17;	DB 6;	Length 17;
	Best Local Similarity	76.5%;	Pred. No. 1.8e+03;		
	Matches	13;	Conservative	4;	Mismatches 0;
					Indels 0;
					Gaps 0;
Oy	1	CUGAGUUUAAAAGGCAC	17		
		:			
Db	1	CTGAGTTTAAAAGGCAC	17		

RESULT 2	AR191755	Sequence 7243 from patent US 6346398.	17 bp	DNA	linear	PAT 20-APR-2002
LOCUS	AR191755	Sequence 7243 from patent US 6346398.				
DEFINITION	AR191755	Sequence 7243 from patent US 6346398.				
ACCESSION	AR191755	Sequence 7243 from patent US 6346398.				
VERSION	AR191755.1	GI:20237720				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	1 (bases 1 to 17)					
AUTHORS	Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.					

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7243 12-FEB-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 81.0%; Score 17; DB 6; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+03;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|:|||||
Db 1 CTGAGTTTAAAGGCAC 17

RESULT 3
LOCUS AR322637 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 39 from patent US 6566127.
ACCESSION AR322637
VERSION AR322637.1 GI:33708445
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 39 20-MAY-2003;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

ORIGIN

Query Match 81.0%; Score 17; DB 6; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+03;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|:|||||
Db 1 CTGAGTTTAAAGGCAC 17

RESULT 4
LOCUS AR489901/c 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 24 from patent US 6710174.
ACCESSION AR489901
VERSION AR489901.1 GI:47257014
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 24 23-MAR-2004;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN

Query Match 81.0%; Score 17; DB 6; Length 20;
Best Local Similarity 76.5%; Pred. No. 1.7e+03;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|:|||||
Db 17 CTGAGTTTAAAGGCAC 1

RESULT 5
LOCUS AR186005 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1493 from patent US 6346398.
ACCESSION AR186005
VERSION AR186005.1 GI:20231970
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 1493 12-FEB-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 76.2%; Score 16; DB 6; Length 17;
Best Local Similarity 75.0%; Pred. No. 5.8e+03;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 16
|:|||||
Db 2 CTGAGTTTAAAGGCAC 17

RESULT 6
LOCUS AR191754 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7242 from patent US 6346398.
ACCESSION AR191754
VERSION AR191754.1 GI:20237719
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7242 12-FEB-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 76.2%; Score 16; DB 6; Length 17;
Best Local Similarity 75.0%; Pred. No. 5.8e+03;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 16
|:|||||
Db 2 CTGAGTTTAAAGGCAC 17

RESULT 7
LOCUS AR322636 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 38 from patent US 6566127.
ACCESSION AR322636
VERSION AR322636.1 GI:33708444
KEYWORDS .
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 38 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
ORIGIN
Query Match 76.2%; Score 16; DB 6; Length 17;
Best Local Similarity 75.0%; Pred. No. 5.8e+03;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAAGGCA 16
Db 2 CTGAGTTTAAAAGGCA 17
RESULT 8
AR489902/c
LOCUS AR489902 25 from patent US 6710174. 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 25 from patent US 6710174.
ACCESSION AR489902
VERSION AR489902.1 GI:47257015
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 25 23-MAR-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
ORIGIN
Query Match 76.2%; Score 16; DB 6; Length 20;
Best Local Similarity 81.2%; Pred. No. 5.6e+03;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 4 AGUUUAAAAGGCACCC 19
Db 20 AGTTTAAAAGGCACCC 5
RESULT 9
AR186004
LOCUS AR186004 1492 from patent US 6346398. 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1492 from patent US 6346398.
ACCESSION AR186004
VERSION AR186004.1 GI:20231969
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 1492 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"
ORIGIN

Query Match 71.4%; Score 15; DB 6; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+04;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CTGAGTTTAAAAGGC 17
RESULT 10
AR191753
LOCUS AR191753 7241 from patent US 6346398. 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7241 from patent US 6346398.
ACCESSION AR191753
VERSION AR191753.1 GI:20237718
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7241 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"
ORIGIN
Query Match 71.4%; Score 15; DB 6; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+04;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CTGAGTTTAAAAGGC 17
RESULT 11
AR322635
LOCUS AR322635 37 from patent US 6566127. 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 37 from patent US 6566127.
ACCESSION AR322635
VERSION AR322635.1 GI:33708443
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 37 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
ORIGIN
Query Match 71.4%; Score 15; DB 6; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+04;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CTGAGTTTAAAAGGC 17
RESULT 12
BD233486/c
LOCUS BD233486 22 bp DNA linear PAT 17-JUL-2003
DEFINITION Novel human thrombopoietin derivative having elevated capability of

```

proliferating platelets in vivo.
BD233486
VERSION BD233486.1 GI:33043256
KEYWORDS JP 2002519031-A/5.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 22)
AUTHORS Chung,J.Y., Park,S.K., Ju,S.M., Kyung,H., Ahn, Lim,S.W.,
Chang,W.I., Park,S.K., Koh,Y.W. and Park,J.S.
TITLE Novel human thrombopoietin derivative having elevated capability of
proliferating platelets in vivo
JOURNAL Patent: JP 2002519031-A 5 02-JUL-2002;
DAEWONG PHARMACEUTICAL CO LTD
COMMENT OS Artificial Sequence
PN JP 2002519031-A/5
PD 02-JUL-2002
PF 30-JUN-1999 JP 2000557365
PR 30-JUN-1998 KR 199825935, 29-JUN-1999 KR 199925143 PI
JOO YOUNG CHUNG, SANG KYU PARK, SANG MYOUNG JU, HYEY KYUNG PI
AHN, SEUNG WOOK LIM,
PI WOO IK CHANG, SEUNG KOOK PARK, YEO WOOL KOH, JI SOO PARK PC
C12N15/09, A61K38/22, A61P7/00, A61P7/04, A61P43/00, A61P43/00, PC
C12N5/10.
CC Synthetic oligodeoxynucleotide primer, 30-N
FH Key Location/Qualifiers
FT source 1..22
FEATURES
source Location/Qualifiers
1..22 /organism='Artificial Sequence'.
/organisms='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
ORIGIN
Query Match 67.6%; Score 14.2; DB 6; Length 22;
Best Local Similarity 68.4%; Pred. No. 4.7e+04;
Matches 13; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGCACCC 19
| | | | | | | | | | | | | | |
Db 19 CAGAGTTTAAACGGAACCC 1

RESULT 13
BD233487
LOCUS Novel human thrombopoietin derivative having elevated capability of
DEFINITION proliferating platelets in vivo.
ACCESSION BD233487
VERSION BD233487.1 GI:33043257
KEYWORDS JP 2002519031-A/6.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 24)
AUTHORS Chung,J.Y., Park,S.K., Ju,S.M., Kyung,H., Ahn, Lim,S.W.,
Chang,W.I., Park,S.K., Koh,Y.W. and Park,J.S.
TITLE Novel human thrombopoietin derivative having elevated capability of
proliferating platelets in vivo
JOURNAL Patent: JP 2002519031-A 6 02-JUL-2002;
DAEWONG PHARMACEUTICAL CO LTD
COMMENT OS Artificial Sequence
PN JP 2002519031-A/6
PD 02-JUL-2002
PF 30-JUN-1999 JP 2000557365
PR 30-JUN-1998 KR 199825935, 29-JUN-1999 KR 199925143 PI
JOO YOUNG CHUNG, SANG KYU PARK, SANG MYOUNG JU, HYEY KYUNG PI
AHN, SEUNG WOOK LIM,
PI WOO IK CHANG, SEUNG KOOK PARK, YEO WOOL KOH, JI SOO PARK PC
C12N15/09, A61K38/22, A61P7/00, A61P7/04, A61P43/00, A61P43/00, PC
C12N5/10.

```

REFERENCE 1 (bases 1 to 28)
 AUTHORS England, S. and Chen, C.
 TITLE PROTON GATED ION CHANNEL PROTEINS
 JOURNAL Patent: WO 9911784-A 6 11-MAR-1999;
 ENGLAND STEVE (GB); UNIV LONDON (GB)
 FEATURES Location/Qualifiers
 source 1..28
 /organism="Rattus sp."
 /mol_type="unassigned DNA"
 /db_xref="taxon:10118"
 /tissue_type="DORSAL ROOT GANGLION"

ORIGIN

Query Match 65.7%; Score 13.8; DB 6; Length 28;
 Best Local Similarity 76.5%; Pred. No. 7.2e+04;
 Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 3 GAGUUUAAAGGCACCC 19
 |||::|||||
 Db 18 GAGGTAAAGGCTCCC 2

Search completed: August 19, 2005, 00:47:36
 Job time : 1662 secs

This Page Blank (uspto)